Resveratrol-induced p53-independent apoptosis of human nasopharyngeal carcinoma cells is correlated with the downregulation of Δnp63

Cancer Gene Therapy

Volumn 17, Issue 12, 2010, Pages 872-882

  Chow, S E ^a   Wang, J S ^a   Chuang, S F ^b   Chang, Y L ^a   Chu, W K ^a   Chen, W S ^a   Chen, Y W ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

DNp63; apoptosis; NPC; resveratrol

Indexed keywords

BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; PROTEIN P63; RESVERATROL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; THERAPY EFFECT; UPREGULATION;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; NASOPHARYNGEAL NEOPLASMS; RNA, SMALL INTERFERING; STILBENES; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

RICE STRIPE VIRUS;

EID: 78349305821     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.44     Document Type: Article

References (47)

1. Crook T, Nicholls J, Brooks L, ON J, Allday MJ. High level expression of Delta N-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene. 2000. 19. 3439-3444.
2. Shi W, Bastianutto C, Li A, Perez-Ordonez B, Ng R, Chow KY et al. Multiple dysregulated pathways in nasopharyngeal carcinoma revealed by gene expression profiling. Int J Cancer 2006; 119: 2467-2475.
3. Chou J, Lin Y-C, Kim J, You L, Xu Z, He B et al. Nasopharyngeal carcinoma\review of the molecular mechanisms of tumorigenesis. Head Neck 2008; 30: 946-963.
4. Chiang CT, Chu WK, Chow SE, Chen JK. Overexpression of delta Np63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation. J Cell Physiol 2009; 219: 117-122.
5. Urist MJ, Di Como CJ, Lu M-L, Charytonowicz E, Verbel D, Crum CP et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002; 161: 1199-1206
6. Mills AA. p63: oncogene or tumor suppressor? Curr Opin Genet Dev 2006; 16: 38-44.
7. DeYoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007; 26: 5169-5183.
8. Moll UM, Slade N. p63 and p73: roles in development and tumor formation. Mol Cancer Res 2004; 2: 371-386.
9. Muller M, Schleithoff ES, Stremmel W, Melino G, Krammer PH, Schilling T. One, two, three\p53, p63, p73 and chemosensitivity. Drug Resist Updat 2006; 9: 288-306.
10. Rocco JW, Leong C-O, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45-56.
11. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill D et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97: 5462-5467.
12. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316.
13. King KE, Ponnamperuma RM, Yamashita T, Tokino T, Lee L, Young M et al. [Delta]Np63[alpha] functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes. Nature 2003; 22: 3635-3644.
14. Athar M, Back J, Tang X, Kim K, Kopelovich L, Bickers D et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224: 274-283.
15. Aziz M, Shannon R, Wu J, Longley BJ, Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J 2005; 421: 277-279.
16. Jang M, Cai L, Udeani G, Slowing KV, Thomas CF, Beecher CWW et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220.
17. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev 2004; 22: 169-188.
18. Chen JK, Chow S. Antioxidants and myocardial ischemia: reperfusion injuries. Chang Gung Med J 2005; 28: 369-377.
19. Chow SE, Hshu YC, Wang JS, Chen JK. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 2007; 102: 1520-1527.
20. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-196.
21. Valenzano DR, Terzibasi E, Genade T, Cattaneo A, Domenici L, Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2006; 16: 296-300.
22. Fulda S, Debatin K. Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review. Cancer Detect Prev 2006; 30: 217-223.
23. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003; 17: 1975-1985.
24. Lin CT, Wong CI, Chan WY, Tzung KW, Ho JK, Hsu MM et al. Establishment and characterization of two nasophary-ngeal carcinoma cell lines. Lab Invest 1990; 62: 713-724.
25. Cheng CC, Wang DY, Kao MH, Chen JK. The growth-promoting effect of KGF on limbal epithelial cells is mediated by u. J Cell Sci 2009; 122: 4473-4480.
26. Baur J, Sinclair D. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
27. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004; 23: 6702-6711.
28. Lee HO, Lee JH, Choi E, Seol JY, Yun Y, Lee H. A dominant negative form of p63 inhibits apoptosis in a p53-independent manner. Biochem Biophys Res Commun 2006; 344: 166-172.
29. Ratovitski EA, Patturajan M, Hibi K, Trink B, Yamaguchi K, Sidransky D. p53 associates with and targets Delta Np63 into a protein degradation pathway. Proc Natl Acad Sci USA 2001; 98: 1817-1822.
30. Sayan BS, Sayan AE, Yang AL, Aqeilan RI, Candi E, Cohen GM et al. Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis. Proc Natl Acad Sci USA 2007; 104: 10871-10876.
31. Chu WK, Lee KC, Chow SE, Chen JK. Dual regulation of the DeltaNp63 transcriptional activity by DeltaNp63 in human nasopharyngeal carcinoma cell. Biochem Biophys Res Commun 2006; 342: 1356-1360.
32. Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P, Caron de Fromentel C. The expression of TA and [Delta]Np63 are regulated by different mechanisms in liver cells. Oncogene 2004; 24: 512-519.
33. Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002; 8: 893-903.
34. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 1998; 421: 277-279.
35. Guo C, Pan ZG, Li DJ, Yun JP, Zheng MZ, Hu ZY et al. The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection. J Transl Med 2006; 4: 23.
36. Yip Y, Tsao S. Regulation of P63 expression in primary and immortalized nasopharyngeal epithelial cells. Int J Oncol 2008; 33: 713-724.
37. Liefer KM, Koster MI, Wang XJ, Yang A, McKeon F, Roop DR. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000; 60: 4016-4020.
38. Murray-Zmijewski F, Lane DP, Bourdon JC. p53//p63//p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13: 962-972.
39. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999; 104: 263-269.
40. Sherr CJ. Principles of tumor suppression. Cell 2004; 116: 235-246.
41. Harmes DC, Bresnick E, Lubin EA, Watson JK, Heim KE, Curtin JC et al. Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. Oncogene 2003; 22: 7607-7616.
42. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006; 5: 14.
43. Mates JM, Sanchez-Jimenez FM. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol 2000; 32: 157-170.
44. Yan W, Chen X. GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J Biol Chem 2006; 281: 7856-7862.
45. Zangen R, Ratovitski E, Sidransky D. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4: 1313-1315.
46. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Antic-ancer Agents 2003; 3: 77-93.
47. Boocock D, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP et al. Phase I dose escalation pharmacoki-netic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16: 1246-1252.